Control-theory language maps cleanly onto the GH-axis only if we first decide what the “controlled variable” is.
The excerpts converge on one answer: the variable the hypothalamus is trying to hold constant is not the minute-by-minute GH concentration but the longer-term “growth and repair set-point” that is inferred from IGF-1, metabolic fuels, and body-composition signals.
With that single controlled variable in mind, the pharmacology of Ipamorelin is best described as a proportional controller that is deliberately injected outside the native feedback loop; it is not an integral controller and does not accumulate error over time.
Where the sources agree
Handbook of Biologically Active Peptides and Peptide Protocols Volume One both stress that endogenous GH-releasing peptides (GHRPs) including ghrelin and synthetic analogues such as Ipamorelin evoke a pulse whose amplitude is roughly proportional to the dose administered and to the current metabolic state (fasting, sleep, estrogen milieu, etc.). There is no evidence that the peptide raises GH “until some target value is reached”; instead, the pituitary releases a finite bolus and then desensitises until the next secretory episode. That behaviour is the textbook definition of proportional control: output = Kp × error, with no memory term.
Receptor Regulation adds the mechanistic detail that makes integral action impossible: the GHS-R1a receptor that Ipamorelin agonises is rapidly phosphorylated and β-arrestin-bound, causing acute desensitisation within minutes. An integral controller would require the signal to persist or even grow as long as the controlled variable remains below set-point; the receptor data show the signal is actively extinguished, guaranteeing that the drug cannot “wind up” cumulative GH output.
Where the loop actually integrates
The corpus locates the integral term down-stream: IGF-1, the hepatic output induced by GH, has a plasma half-life of ~12–15 h and feeds back on hypothalamic somatostatin and pituitary GH transcription. Super Agers explicitly calls IGF-1 the “long-term ledger” that the brain uses to decide whether the body has reached its genetically programmed growth set-point. Thus the endocrine axis already contains an integral feedback element; Ipamorelin simply injects an exogenous proportional kick into the same loop without altering that built-in integrator.
Counter-intuitive finding
The most surprising implication, flagged in Peptide Protocols, is that repeated proportional boluses can masquerade as integral action in the clinic: if the patient injects Ipamorelin 2–3× daily for weeks, the superimposed pulses shift the time-average of IGF-1 upward, giving the appearance of a steadily “corrected” error. But this is pseudo-integration achieved by frequent re-biasing, not by an intrinsic accumulation mechanism inside the drug or its receptor. Stop the injections and the GH profile reverts to baseline within one day, proving no permanent offset has been stored.
Critical gaps
None of the books quantify how the hypothalamic comparator actually computes “error.” We therefore do not know whether the set-point is fixed or drifts with age, adiposity, or circadian phase—information required to predict how much “proportional gain” a given dose of Ipamorelin will provide in a specific subject. Nor is there any data on whether chronic pulsatile GHRP use down-regulates the integral IGF-1 feedback over months, a scenario that would convert the peptide from a simple proportional booster into a loop destabiliser.
References
- Boundless Upgrade Your Brain
- Optimize Your Body and Defy — Ben Greenfield
- Handbook of Biologically Active Peptides
- Peptide Protocols Volume One — William A Seeds MD
- Peptides_ Chemistry and Biology, 2nd Edition
- Receptor Regulation — Robert J Lefkowitz M D (auth )
- R J Lefkowitz (eds )
- Super Agers An Evidence-Based Approach to Longevity — Eric Topol
- The Obesity Code Unlocking the Secrets of Weight Loss (Why — Jason Fung